CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed the investor presentation to be made to select investors on Wednesday February 12, 2020 at Mumbai in IIFL Investor Conference. Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed a copy of press release dated February 11, 2020 titled 'Zydus receives final approval from the USFDA for Fluocinonide Cream USP, 0.1%.'
Cadila Health gains 3% on Establishment Inspection Report from USFDA
The topical manufacturing facility had completed the USFDA audit during December 16-20, 2019. Cadila Healthcare Ltd - 532321 - Notification
Company's topical manufacturing facility located at Ahmedabad, India has received an Establishment Inspection Report (EIR) from the USFDA signifying the successful closure of the audit. The topical manufacturing facility had completed the USFDA audit from 16th to 20th December 2019 with zero 483 observations.
Hold Cadila Healthcare; target of Rs 247: Prabhudas Lilladher
Prabhudas Lilladher recommended hold rating on Cadila Healthcare with a target price of Rs 247 in its research report dated February 06, 2019.
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the unaudited financial results for the quarter / nine months ended on December 31, 2019. Cadila Healthcare Ltd - 532321 - Unaudited Financial Results
Unaudited Financial results for the quarter / half year ended on December 31, 2019 Cadila Healthcare Ltd - 532321 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Loss of Share Certificate / Issue of Duplicate Share Certificate. CADILA HEALTHCARE LTD. - 532321 - Notification
We hereby inform that the USFDA inspected the manufacturing facility of Alidac Pharmaceuticals Ltd., the company's wholly-owned subsidiary, located at SEZ, Ahmedabad from 27th January to 4th February 2020. At the end of the inspection, no observation (483) is issued. The site manufactures oncology injectables for the regulated markets.